MeCure Industries Plc, (MECURE) has reported a strong growth in its unaudited nine-month results ending September 30, 2025, the financial statements released by the company, shows the revenue climbed 99% to N60.01 nearly doubled from N30.22 billion in 2024.
This was driven by increased product demand, yielding a gross profit of N20.41 billion (up 104%).
Operating profit surged 159% to N13.02 billion, despite higher marketing and administrative expenses at N2.64 billion and N4.89 billion, respectively.
Finance costs rose to N6.65 billion amid elevated borrowing, but profit before tax reached N6.37 billion (up 186%), with net profit at N4.46 billion (up 186%) and earnings per share at N1.11 (from N0.39).
Total assets grew 43% to N78.23 billion, including property, plant, and equipment at N42.67 billion, while equity increased to N17.82 billion on retained profits of N15.82 billion. Liabilities climbed to N60.41 billion, with commercial papers jumping to N28.73 billion.
Shareholding remains concentrated, with founders holding over 86% and a compliant free float of 12.73% valued at N6.62 billion.
No dividends were proposed, and the board, led by Chairman Samir Udani and co-CEOs Dukor Anderline Ndidi and Arjun Udani, affirmed effective internal controls and going concern status.
Auditors Alexander Johnson & Co. ended their tenure, with no donations made during the period.
MeCure Industries Plc, a prominent Nigerian pharmaceutical company specializing in the manufacturing and distribution of pharmaceutical and multivitamin products, Incorporated in 2005 and transitioning to a public limited liability company in late 2022.
MeCure operates from its corporate office in Oshodi, Lagos, and continues to solidify its position in the healthcare sector
Administrator and Writer
